Advertisement Enamine Extends Multi-Year Drug Discovery Collaboration with Lundbeck - Pharmaceutical Business review

Advertisement

Pharmaceutical Business review is using cookies

ContinueLearn More
Close
More info about Enamine

Enamine Extends Multi-Year Drug Discovery Collaboration with Lundbeck

Enamine, a provider of integrated drug discovery services empowered by the world’s largest collections of building blocks and screening compounds, and H. Lundbeck A/S (Lundbeck), the global pharmaceutical company involved in the research of new drugs for the treatment of disorders in the central nervous system, today announced the expansion of their research collaboration.

Enamine will support Lundbeck’s in-house discovery chemistry competencies with three principal assets enabling Lundbeck to optimally identify and develop hit series in its multiple research programs.

  • A large diverse library of 100,000 new screening compounds for hit finding activities on numerous therapeutic targets.
  • Enamine’s make-on-demand REAL compounds (Nature, 2019, Vol. 566, p. 224–229) for efficient access to billions of novel chemical compounds.
  • An increased dedicated team of Enamine FTE chemists to effectively support Lundbeck on all hit related follow-up activities backed by immediate access to over 170,000 building blocks in Enamine’s inventory.

Lundbeck Director and Head of Medicinal Chemistry Dr Paul Kilburn said: “Enamine’s REAL Database is allowing us to expedite our hit explosion programs at unmatched speed and synthesis success. We look forward to the results of our HTS campaigns and to continue receiving highly valuable compounds exclusively synthesized for us.”

Enamine Head of Strategic Alliances Michael Bossert commented: “We are delighted to extend our collaboration with Lundbeck, with whom we have a strong historical relationship. This reflects the high-performance level already achieved and a confidence mutually shared, which is most gratifying.”